AMGN and REGN Related Headlines
Go Back- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- Trump to announce prescription drug price agreements
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
- William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
- Regeneron (REGN) See Strength Following Opening Bell Weakness, Now up Over 2pct
- Regeneron (REGN) Shares Decline on the Open
- Raymond James Comments on REGN and AMGN Earlier
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
- White House: Trump took action on pharma Thursday, sent letters to CEOs
- Biotech stocks dip as Trump administration mulls patent fee overhaul
AMGN and REGN Related Press Releases
Go Back- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
